Welcome to our dedicated page for Oncotelic Therapeutics news (Ticker: OTLC), a resource for investors and traders seeking the latest updates and insights on Oncotelic Therapeutics stock.
Oncotelic Therapeutics Inc (OTLC) is a clinical-stage biopharmaceutical company advancing innovative therapies for cancer treatment through precision medicine and targeted drug development. This page consolidates official news releases and verified updates, providing stakeholders with a reliable resource for tracking the company’s progress in oncology research.
Investors and industry observers will find timely information on clinical trial milestones, regulatory developments, and strategic partnerships with pharmaceutical collaborators. The curated news feed also covers financial disclosures and operational updates critical for assessing OTLC’s position in the competitive oncology therapeutics market.
Content is organized to highlight key areas of interest including R&D advancements, technology innovations, and corporate governance updates. Regular visitors can stay informed about the company’s efforts to address unmet medical needs through its pipeline of novel cancer therapies.
Bookmark this page for direct access to Oncotelic Therapeutics’ latest announcements, or subscribe to Stock Titan’s alerts for real-time updates on OTLC’s developments in oncology research and biopharmaceutical collaborations.
Oncotelic Therapeutics (OTLC) has signed an exclusive licensing agreement with Autotelic Inc. for the development of AL-101, an intranasal apomorphine treatment targeting Parkinson's Disease and Erectile Dysfunction. The company aims to leverage the 505(b)2 regulatory pathway to expedite AL-101's market entry, having completed six clinical trials involving over 200 patients. Given the rising incidence of Parkinson's and unmet needs in sexual dysfunction, the acquisition positions Oncotelic for significant growth in these markets.
Oncotelic Therapeutics (OTCQB:OTLC) has signed a binding term sheet with Autotelic Inc. to license AL-101, an intranasal apomorphine aimed at treating Parkinson Disease (PD), Erectile Dysfunction (ED), and Female Sexual Dysfunction (FSD). This product will utilize the fast-to-market 505(b)2 regulatory pathway. AL-101 has completed six clinical trials with over 200 patients, demonstrating safety and efficacy. The growing incidence of PD and ED highlights the potential market for AL-101, offering a new therapeutic alternative for treatment-resistant patients.
Oncotelic Therapeutics (OTCQB:OTLC) announced positive results from its ARTI-19 clinical trial assessing PulmoHeal/ArtiVeda for treating mild to moderate COVID-19. The study demonstrated significant efficacy, with the artemisinin+SOC group showing faster improvement in WHO severity scale scores and respiratory metrics compared to standard of care. No serious side effects were reported, and the treatment was well-tolerated. This promising data will support Oncotelic's regulatory submission for marketing approval. The company aims to expand PulmoHeal/ArtiVeda's market presence as phytomedicine.
Oncotelic Therapeutics (OTCQB:OTLC) has formed a joint venture with Golden Mountain Partners to accelerate the clinical development of its pharmaceutical pipeline. An initial investment of $1.5 million from GMP aims to enhance commercialization efforts. This partnership builds on a relationship that began in 2020, focusing on therapies for oncology and COVID-19. Oncotelic plans to pursue an initial public offering (IPO), looking to replicate recent successes in TGF-β asset IPOs. The CEO expresses optimism for swift advancements in treatment availability.
Oncotelic Therapeutics (OTCQB:OTLC) has announced the discontinuation of enrollment in its OT-101 clinical trial for COVID-19 patients, having randomized 32 out of the planned 36 patients. This decision was motivated by the rise of severe COVID-19 variants in Latin America, which strained medical infrastructure. The trial aimed to assess the role of TGF-beta in COVID-19 and expected to provide significant biomarker data. The company's lead drug, OT-101, targets TGF-β linked to COVID-19 symptoms and is the only therapeutic of its kind currently being evaluated.
Oncotelic Therapeutics (OTCQB:OTLC) is collaborating with the Chopra Foundation and Heart Care Foundation to provide COVID-19 relief in India, supplying medicines including PulmoHeal™, which aids respiratory recovery. PulmoHeal™ is available OTC and is designed to address unmet medical needs amidst a surge of over 400,000 daily cases in India. The initiative aims to gather data on various COVID-19 treatments through a Post Marketing Survey platform. This humanitarian effort combines PulmoHeal™ with oxygen support, enhancing immediate and long-term recovery for affected patients.
Oncotelic Therapeutics (OTLC) announced positive results from its COVID-19 clinical trial, ARTI-19, evaluating PulmoHeal™ in India. The trial demonstrated no adverse events requiring treatment discontinuation, with 91% of patients achieving improved conditions. Key findings include normalized vital signs and significant improvements in oxygen saturation and respiratory rates by day 28. PulmoHeal™, developed in partnership with Windlas Biotech, has potential for broad-spectrum antiviral efficacy, confirmed against multiple SARS-CoV-2 variants.
Oncotelic Therapeutics, Inc. (OTCQB:OTLC) announced a presentation at AACR-2021 discussing a combination therapy using Trabedersen, an anti-sense oligonucleotide targeting TGF-β2, and Proleukin (IL-2) for treating solid cancers. This approach aims to enhance immune response while mitigating IL-2 toxicity. In vitro studies showed reduced cancer cell viability and significant tumor growth delay in humanized mouse models. Oncotelic also received regulatory approval for a phase 1b trial of the OT-101/IL-2 combination, further supporting its innovative cancer treatment pipeline.
Oncotelic Therapeutics (OTCQB:OTLC) announced a collaboration with the Chopra Foundation and Jiva to host a webinar titled Ayurvedic Perspectives on COVID-19 on April 15, 2021. The event will feature experts discussing various aspects of COVID-19 management, including inflammation and Ayurvedic approaches. Notably, Oncotelic's PulmoHeal includes a mobile app for monitoring respiratory health and a lung therapy supplement that has demonstrated efficacy against COVID-19. The company continues to focus on leveraging AI for health assessments amid the ongoing pandemic.
Oncotelic Therapeutics (OTCQB:OTLC), formerly known as Mateon Therapeutics, announced on March 30, 2021, that the Financial Industry Regulatory Authority (FINRA) has approved its name and ticker symbol change. The new ticker symbol, effective immediately, is OTLC, replacing MATN. This follows a corporate action approved by shareholders in August 2020, which included the name change finalized in November 2020. Oncotelic focuses on developing RNA therapeutics and small molecule drugs targeting cancer and infectious diseases, particularly emphasizing rare pediatric cancers.
